Company Overview
American Healthcare Capital is proud to represent a disruptive medical device company in the interventional oncology space. This company is redefining how tumors are treated. By combining tumor-injected nanotechnology with a proprietary activation device, its system provides doctors with the ability to confirm tumor targeting in vivo before treatment, an innovation that sets a new standard in safety and precision.
Why Now?
- Rising early-stage lung cancer cases due to new screening programs result in increasing number of patients who need minimally invasive treatments.
- In those early-stage cases, traditional therapies like surgery and radiation are often too aggressive and/or too risky.
- Investors are rewarding innovation: recent deals in the space include multi-billion-dollar acquisitions.
The Opportunity
The company is initially targeting the U.S. lung cancer market, projected to deliver $150 million in revenue over the next several years. With expansion into additional cancers and global markets, total revenue potential exceeds $350 million annually.
Key Highlights
- Clinically validated technology in brain and prostate cancers.
- CE Mark approval in Europe for the nanoparticle and activating devices
- More than $120 million invested to date in R&D, patents, and infrastructure.
- Strong management team with global experience in oncology, medical devices, and finance.
- U.S. regulatory pathway with commercial launch targeted in 2028.
Funding Needs, Exit Strategy, and Deal Structure
The Company is seeking a staged investment of $22 million to accelerate the expansion of its U.S. footprint and capture significant market share in a rapidly growing sector. Management is open to a range of deal structures, including a majority equity sale, to ensure alignment with the right strategic or financial partner. This investment is designed to fuel scalability, drive faster adoption, and unlock substantial long-term value for investors. The Company’s valuation will be established through thoughtful discussion and negotiation, with an emphasis on creating an attractive return profile for all parties involved. The Company would also consider an outright sale of its activating device while maintaining rights to and further developing the nanotechnology, which the device activates.
